An mRNA influenza vaccine bests an inactivated quadrivalent flu vaccine against two different strains in phase 3 study.

A new mRNA vaccine against the flu has proven itself more effective than existing vaccines in a new clinical trial. The ...

Pfizer started its 25,000-person phase 3 trial Sept. 14 to test the efficacy of a flu vaccine candidate that uses the same mRNA technology as its COVID-19 vaccine. In mid-June, Moderna began enrolling ...

NEW YORK -- When the final Phase 3 data came out last November showing the mRNA vaccines made by Pfizer/BioNTech and Moderna were more than 90% effective, Dr. Anthony Fauci had no words. He texted ...

When you buy through links on our articles, Future and its syndication partners may earn a commission. MRNA technology was thrust into the limelight during the COVID-19 pandemic, but had been in ...

A recent study has provided the first side-by-side comparison of how three major COVID-19 vaccine types differ in triggering ...

A messenger RNA combination vaccine that Pfizer and BioNTech are developing for both Covid-19 and influenza posted mixed results in a pivotal study, meeting just one of the two main goals assessing ...

The Department of Health and Human Services will cancel 22 vaccine development projects totaling $500 million, marking a major policy shift under Secretary Robert F. Kennedy Jr. that directly affects ...

WASHINGTON (AP) — So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel Prize-winning technology to try to develop vaccines and ...

Pfizer Inc. (NYSE:PFE) and Moderna Inc. (NASDAQ:MRNA) are set for more legal battles over their rival COVID-19 vaccines after London’s High Court delivered a mixed ruling on two of Moderna’s patents.